As far as I know, the latest relevant info from the FDA was on 28 Feb 2019, more than 3 years ago. I would hope that since then that issue of toxic contaminants in valsartan was cleared up. Ask your MD or pharmacist if they know anything more recent.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan
Here's the text & table in that 28 Feb 2019 valsartan update:
Update [2/28/2019] FDA is posting the updated table of interim acceptable intake limits for nitrosamine impurities to reflect N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) limits, which are the same as those for NDMA.
The agency will use the interim limits below to recommend manufacturers conduct a voluntary recall if laboratory testing confirms the presence of nitrosamine impurities in finished drug product. FDA is working with industry and international regulators to ensure products entering the market do not contain these impurities, but we are tolerating the impurities below the level established in the table for a short period of time to avoid a possible shortage of ARBs.
Not all ARB products contain NDMA, NDEA or NMBA impurities, so pharmacists may be able to provide an alternative medication not affected by the recalls, or health care professionals may prescribe a different medication that treats the same condition.
* The acceptable intake is a daily exposure to a compound such as NDMA, NDEA, or NMBA that approximates a 1:100,000 cancer risk after 70 years exposure.
** These values are based on a drug's maximum daily dose as reflected in the drug label.
*** FDA is temporarily not objecting to losartan with NMBA below 9.82 ppm remaining on the market.